TeraDiscoveries has formed a strategic partnership with Egenix, a privately held New York-based biotechnology firm. The two companies are working together to design new drugs to treat cancer and autism.
TeraDiscoveries will use its Inverse Design software platform to design new drug molecules to effectively help Egenix accelerate its drug discovery and development process. Egenix is providing funding and target data that TeraDiscoveries will apply to identify and optimize inhibitors for certain cancer indications and autism. Egenix will develop the drugs through phase II, while TeraDiscoveries retains a minority stake in the two drugs.
Inverse Design runs computational models to quickly scan a vast chemical space to find the strongest inhibitors of a specific biological target, ones that also have good druggable properties and are predicted to have low toxic side effects. Inverse Design also has filters for many important drug properties including toxic side-effect risk assessment, off-target effects assessment, synthesizability, solubility and freedom to operate assessment. Specialized filtering can assess if a molecule crosses the blood-brain barrier.
Companies can use Inverse Design as a service and run it via the Windows Azure cloud or a private cloud to design, discover or optimize new small molecule or peptide drugs for their targets. TeraDiscoveries also partners and licenses assets in its pipeline which include compounds for many targets including Jak2, Jak3, hdac8, Aurora A, 11b-HSD1, hsp90, MAPK10, pfDHFR-Ts, ABL1, ABL3, ROCK1, TYK2 and c-Kit.